 |
6 Diseases |  |
1 Trial |
|
1 Trial |  |
67 News |  |
| «12 |
- GSK2982772 / GSK
Trial primary completion date: Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jul 7, 2017
P2, N=30, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2018 --> Sep 2018
- ||| GSK2982772 / GSK
Enrollment change: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (clinicaltrials.gov) - May 25, 2017
P2, N=54, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2018 --> Sep 2018 N=30 --> 54
- |||| GSK2982772 / GSK
Enrollment open: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (clinicaltrials.gov) - Apr 10, 2017
P2, N=30, Recruiting, Sponsor: GlaxoSmithKline
N=30 --> 54 Active, not recruiting --> Recruiting
- || GSK2982772 / GSK
Trial primary completion date: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (clinicaltrials.gov) - Apr 7, 2017
P2, N=30, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Recruiting Trial primary completion date: May 2017 --> Jan 2018
- | GSK2982772 / GSK
Clinical: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (clinicaltrials.gov) - Feb 8, 2017
P2, N=30, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2017 --> Jan 2018 Recruiting --> Active, not recruiting
- | GSK2982772 / GSK
Enrollment open: GSK2982772 Study in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Dec 6, 2016
P2, N=36, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | GSK2982772 / GSK
Enrollment change: GSK2982772 Study in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Nov 8, 2016
P2, N=36, Not yet recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=48 --> 36
- | GSK2982772 / GSK
Enrollment open: Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 2, 2016
P2, N=30, Recruiting, Sponsor: GlaxoSmithKline
N=48 --> 36 Not yet recruiting --> Recruiting
- GSK2982772 / GSK
Phase classification: GSK2982772 Study in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Oct 16, 2016
P2, N=48, Not yet recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Phase classification: P2a --> P2
- | GSK2982772 / GSK
New P2 trial, New P2a trial: GSK2982772 Study in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Sep 16, 2016
P2a, N=48, Not yet recruiting, Sponsor: GlaxoSmithKline
- | GSK2982772 / GSK
Clinical: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (clinicaltrials.gov) - Sep 8, 2016
P2, N=30, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P2a --> P2 Not yet recruiting --> Recruiting
- | GSK2982772 / GSK
New P2 trial: Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 8, 2016
P2, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||| GSK2982772 / GSK
New P2 trial: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis (clinicaltrials.gov) - May 18, 2016
P2, N=30, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||| GSK2982772 / GSK
Trial completion: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects (clinicaltrials.gov) - Mar 28, 2016
P1, N=79, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- || GSK2982772 / GSK
Trial primary completion date: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects (clinicaltrials.gov) - Dec 21, 2015
P1, N=76, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Feb 2016
- || GSK2982772 / GSK
Enrollment change: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects (clinicaltrials.gov) - May 4, 2015
P1, N=72, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2015 --> Feb 2016 N=52 --> 72
- ||| GSK2982772 / GSK
Enrollment open: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects (clinicaltrials.gov) - Jan 20, 2015
P1, N=52, Recruiting, Sponsor: GlaxoSmithKline
N=52 --> 72 Not yet recruiting --> Recruiting
- ||| GSK2982772 / GSK
New P1 trial: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects (clinicaltrials.gov) - Nov 28, 2014
P1, N=52, Not yet recruiting, Sponsor: GlaxoSmithKline